29-May-2026
Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor Conference
Business Wire (Thu, 21-May 4:05 PM ET)
Simulations Plus and NVIDIA Partnership Targets 75% Faster Drug Modeling with AI and GPU Power
Market Chameleon (Wed, 6-May 4:12 AM ET)
Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows
Business Wire (Wed, 6-May 7:55 AM ET)
Business Wire (Tue, 21-Apr 7:55 AM ET)
Business Wire (Mon, 20-Apr 7:55 AM ET)
Simulations Plus Grows Revenue and Profits in Q2 2026, Lowers EPS Guidance on Tax Rate Adjustment
Market Chameleon (Fri, 10-Apr 7:07 AM ET)
Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results
Business Wire (Thu, 9-Apr 4:05 PM ET)
Simulations Plus Announces Second Quarter Fiscal Year 2026 Earnings and Conference Call Date
Business Wire (Thu, 26-Mar 4:05 PM ET)
Simulations Plus Announces Strategic Collaboration Programs for AI-Enabled Modeling
Business Wire (Thu, 26-Mar 7:55 AM ET)
Simulations Plus Convenes Industry and Regulatory Leaders to Define Responsible AI in MIDD
Business Wire (Tue, 3-Mar 7:55 AM ET)
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
Simulations Plus trades on the NASDAQ stock market under the symbol SLP.
As of May 29, 2026, SLP stock price climbed to $17.11 with 247,522 million shares trading.
SLP has a beta of 2.24, meaning it tends to be more sensitive to market movements. SLP has a correlation of 0.12 to the broad based SPY ETF.
SLP has a market cap of $345.72 million. This is considered a Small Cap stock.
Last quarter Simulations Plus reported $24 million in Revenue and $.35 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.06.
In the last 3 years, SLP traded as high as $52.69 and as low as $11.09.
The top ETF exchange traded funds that SLP belongs to (by Net Assets): VTI, IWM, VXF, IWO, SCHA.
SLP has underperformed the market in the last year with a return of -46.8%, while SPY returned +29.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in SLP shares. However, SLP has outperformed the market in the last 3 month and 2 week periods, returning +39.9% and +28.3%, while SPY returned +10.5% and +2.3%, respectively. This indicates SLP has been having a stronger performance recently.
SLP support price is $15.99 and resistance is $17.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLP shares will trade within this expected range on the day.
